New Company Joins With RPR To Develop Intrabody Technology

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new company formed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute, has joined the Rhône-Poulenc Rorer Gencell network to help accelerate the development of its innovate intrabody, or intracellular antibody, technology.

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new companyformed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute,has joined the Rhône-Poulenc Rorer Gencell network to helpaccelerate the development of its innovate intrabody, or intracellularantibody, technology.

An intrabody is an engineered human antibody that works insidea cell, offering the potential for blocking molecular changesthat can lead to dis-eases such as cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Related Content